If they're already infected with hepatitis C virus (HCV), patients in need of a kidney transplant might safely receive an organ from an HCV-infected donor, a new study maintains.
GlaxoSmithKline (GSK) has exercised the option to obtain an exclusive global licence from Adaptimmune Therapeutics for an investigational SPEAR T-cell receptor therapy targeting NY-ESO-1 (GSK3377794).